Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a buy rating to a strong-buy rating in a research note issued to investors on Friday morning.

A number of other brokerages have also issued reports on AUPH. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Stock Down 0.2 %

AUPH stock traded down $0.02 during midday trading on Friday, hitting $8.32. 2,230,112 shares of the company’s stock were exchanged, compared to its average volume of 895,188. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.05. The firm has a 50 day moving average price of $7.13 and a 200-day moving average price of $6.11. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -55.47 and a beta of 1.45.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The business had revenue of $67.77 million during the quarter, compared to analyst estimates of $59.07 million. On average, analysts anticipate that Aurinia Pharmaceuticals will post 0.13 EPS for the current year.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several hedge funds have recently bought and sold shares of AUPH. Intech Investment Management LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter worth about $262,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter worth $3,330,000. Segall Bryant & Hamill LLC boosted its stake in shares of Aurinia Pharmaceuticals by 1.6% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock valued at $4,125,000 after purchasing an additional 9,031 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Aurinia Pharmaceuticals by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after buying an additional 10,700 shares during the last quarter. Finally, CWM LLC grew its position in Aurinia Pharmaceuticals by 247.7% during the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 8,180 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.